Syros Pharmaceuticals (NASDAQ: SYRS)
Syros Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Syros Pharmaceuticals Company Info
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
News & Analysis
Why Syros Pharmaceuticals Stock Is Soaring Today
Investors appeared to like the addition of a well-known new board member.
Why IBM, Extraction Oil & Gas, and Syros Pharmaceuticals Slumped Today
Not every stock had a favorable reaction to earnings.
Here's Why Syros Pharmaceuticals Is Collapsing Today
The company announced the pricing of a stock offering. Despite the dilution, it's a well-timed move by management.
Here's Why Syros Pharmaceuticals Got Crushed Today
The small-cap biopharma company announced disappointing results for its lead drug candidate.
Valuation
Earnings Transcripts
Syros Pharmaceuticals, Inc.(SYRS) Q1 2020 Earnings Call Transcript
SYRS earnings call for the period ending March 31, 2020.
Syros Pharmaceuticals, Inc.(SYRS) Q4 2019 Earnings Call Transcript
SYRS earnings call for the period ending December 31, 2019.
Syros Pharmaceuticals, Inc.(SYRS) Q3 2019 Earnings Call Transcript
SYRS earnings call for the period ending September 30, 2019.
Syros Pharmaceuticals, Inc.(SYRS) Q2 2019 Earnings Call Transcript
SYRS earnings call for the period ending June 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.